The Patent Finder

Terms ending in 2040

Cellectis

Every in-force patent on Cellectis's record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 11,903,968Engineered Immune Cells Resistant to Tumor Microenvironment
In force
 · High confidence
CellectisIn forceHigh confidence
US 12,209,125Targeted Gene Integration of NK Inhibitors Genes for Improved Immune Cells Therapy
In force
 · High confidence
CellectisIn forceHigh confidence
US 12,221,478Targeted Gene Integration of CRS Inhibitor Genes for Improved Immune Cells Therapy
In force
 · High confidence
CellectisIn forceHigh confidence
US 12,296,012Chimeric Antigen Receptors Targeting FLT3
In force
 · High confidence
Pfizer Inc.In forceHigh confidence
US 11,767,512New Sequence Specific Reagents Targeting CCR5 in Primary Hematopoietic Cells
In force
 · High confidence
CellectisIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Cellectis.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited